Raymond Wadlow

6.9k total citations
36 papers, 944 citations indexed

About

Raymond Wadlow is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Raymond Wadlow has authored 36 papers receiving a total of 944 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 12 papers in Cancer Research and 9 papers in Molecular Biology. Recurrent topics in Raymond Wadlow's work include Pancreatic and Hepatic Oncology Research (11 papers), Cancer Genomics and Diagnostics (11 papers) and Colorectal Cancer Treatments and Studies (10 papers). Raymond Wadlow is often cited by papers focused on Pancreatic and Hepatic Oncology Research (11 papers), Cancer Genomics and Diagnostics (11 papers) and Colorectal Cancer Treatments and Studies (10 papers). Raymond Wadlow collaborates with scholars based in United States, India and Germany. Raymond Wadlow's co-authors include Sridhar Ramaswamy, David P. Ryan, Lawrence S. Blaszkowsky, Andrew X. Zhu, D. Gary Gilliland, Ian F. Dunn, Anna C. Schinzel, Konstanze Döhner, Stefan Fröhling and Jesse S. Boehm and has published in prestigious journals such as Cell, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Raymond Wadlow

31 papers receiving 922 citations

Peers

Countries citing papers authored by Raymond Wadlow

Since Specialization

Citations

This map shows the geographic impact of Raymond Wadlow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raymond Wadlow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raymond Wadlow more than expected).

Fields of papers citing papers by Raymond Wadlow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raymond Wadlow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raymond Wadlow. The network helps show where Raymond Wadlow may publish in the future.

Co-authorship network of co-authors of Raymond Wadlow

This figure shows the co-authorship network connecting the top 25 collaborators of Raymond Wadlow. A scholar is included among the top collaborators of Raymond Wadlow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raymond Wadlow. Raymond Wadlow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database 2025 ·The Oncologist ·Abrahm Levi, Edik M. Blais, (unknown), (unknown), (unknown), (unknown), Gillian Gresham, Lei Zheng, (unknown), Rachna T. Shroff, Raymond Wadlow, Patricia DeArbeloa, Lynn M. Matrisian, Emmanuel Petricoin, Michael J. Pishvaian, Jun Gong, Andrew Hendifar, Arsen Osipov	0
2	A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer. 2024 ·Journal of Clinical Oncology ·Eric S. Christenson, Daruka Mahadevan, Syed Mohammad Ali Kazmi, Sudhir Manda, Davendra Sohal, Thomas E. Hutson, Siqing Fu, (unknown), (unknown), Emilia Alina Barbu, Dallas B. Flies, Solomon Langermann, Michael Chisamore, Martin Gutierrez, Marc Matrana, (unknown), Raymond Wadlow, (unknown), (unknown), Dung T. Le	2
3	Results of a phase 2 study of evorpacept (E, ALX148), cetuximab (C), and pembrolizumab (P) in patients with refractory microsatellite stable metastatic colorectal cancer (MSS CRC). 2024 ·Journal of Clinical Oncology ·Robert W. Lentz, Patrick J. Blatchford, Junxiao Hu, Todd M. Pitts, Adrie van Bokhoven, Hannah R. Robinson, (unknown), (unknown), Alexis D. Leal, (unknown), S. Lindsey Davis, Christopher H. Lieu, Raymond Wadlow, Kristen Spencer, Aaron J. Scott, Patrick M. Boland, Howard S. Höchster, Wells A. Messersmith	1
4	Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS 2022 ·Cancer Treatment and Research Communications ·Timothy Lewis Cannon, (unknown), Ethan S. Sokol, (unknown), Raymond Wadlow, Arthur Winer, (unknown), (unknown), Halla Nimeiri, Kimberly McGregor	4
5	A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma 2020 ·The Oncologist ·Marc Roth, Dana B. Cardin, Erkut Borazanci, (unknown), Vincent J. Picozzi, (unknown), Raymond Wadlow, Robert A. Newman, Jordan Berlin	27
6	A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer 2020 ·Investigational New Drugs ·Lipika Goyal, Surendra Pal Chaudhary, Eunice L. Kwak, Thomas A. Abrams, (unknown), Brian M. Wolpin, Raymond Wadlow, Jill N. Allen, Rebecca S. Heist, Nadine J. McCleary, Jennifer A. Chan, Wolfram Goessling, Deborah Schrag, (unknown), Peter C. Enzinger, David P. Ryan, Jeffrey W. Clark	17
7	Activity of RX-3117, an oral antimetabolite nucleoside, in subjects with advanced urothelial cancer: Preliminary results of a phase IIa study. 2019 ·Journal of Clinical Oncology ·Nicholas Salgia, Sumanta K. Pal, Vincent Chung, Scott T. Tagawa, Joel Picus, Hani M. Babiker, Sumati Gupta, Raymond Wadlow, (unknown), Christine B. Peterson, Ely Benaim	0
8	Molecular Testing to Optimize and Personalize Decision Making in the Management of Colorectal Cancer. 2017 ·PubMed ·(unknown), Anthony F. Shields, Jimmy J. Hwang, Raymond Wadlow, John L. Marshall	3
9	Capecitabine and oxaliplatin as first and second line treatment for locally advanced and metastatic pancreatic ductal adenocarcinoma 2017 ·Journal of Gastrointestinal Oncology ·Andrea J. Bullock, Keith Stuart, Susanna Jacobus, Thomas A. Abrams, Raymond Wadlow, Michael A. Goldstein, Rebecca A. Miksad	10
10	MP82-09 PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATE (PSMA ADC) IN PATIENTS (PTS) WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) FOLLOWING ABIRATERONE AND/OR ENZALUTAMIDE (ABI/ENZ): RESULTS FROM A PHASE 2 STUDY 2015 ·The Journal of Urology ·Daniel P. Petrylak, Nicholas J. Vogelzang, (unknown), Mark T. Fleming, David C. Smith, Leonard J. Appleman, Arif Hussain, Manuel Modiano, Parminder Singh, Scott T. Tagawa, Ira Gore, (unknown), (unknown), Oliver Sartor, Brad Somer, Raymond Wadlow, Neal D. Shore, Nancy Stambler, Vincent A. DiPippo, Robert J. Israel	3
11	A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma 2014 ·Investigational New Drugs ·Lipika Goyal, Raymond Wadlow, Lawrence S. Blaszkowsky, Brian M. Wolpin, Thomas A. Abrams, Nadine J. McCleary, Susan Sheehan, (unknown), Michael D. Karol, John Chen, Andrew X. Zhu	42
12	Mutational analysis and clinical correlation of metastatic colorectal cancer 2014 ·Cancer ·Andrea Russo, Darrell R. Borger, Jackie Szymonifka, David P. Ryan, Jennifer Y. Wo, Lawrence S. Blaszkowsky, Eunice L. Kwak, Jill N. Allen, Raymond Wadlow, Andrew X. Zhu, Janet E. Murphy, Jason E. Faris, Dora Dias‐Santagata, Kevin M. Haigis, Leif W. Ellisen, A. John Iafrate, Theodore S. Hong	62
13	A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor 2013 ·Cancer ·Jennifer A. Chan, Lawrence S. Blaszkowsky, Keith Stuart, Andrew X. Zhu, Jill N. Allen, Raymond Wadlow, David P. Ryan, Jeffrey A. Meyerhardt, (unknown), Eileen Regan, Hui Zheng, Matthew H. Kulke	64
14	Pancreatic Neuroendocrine Tumors With Involved Surgical Margins: Prognostic Factors and the Role of Adjuvant Radiotherapy 2012 ·International Journal of Radiation OncologyBiologyPhysics ·Nils D. Arvold, Christopher G. Willett, Carlos Fernández‐del Castillo, David P. Ryan, Cristina R. Ferrone, Jeffrey W. Clark, Lawrence S. Blaszkowsky, Vikram Deshpande, Andrzej Niemierko, Jill N. Allen, Eunice L. Kwak, Raymond Wadlow, Andrew X. Zhu, Andrew L. Warshaw, Theodore S. Hong	20
15	Immediate versus delayed adjuvant chemoradiation for resected pancreatic cancer: An analysis of local control and survival. 2012 ·Journal of Clinical Oncology ·Stephanie Childs, Harvey J. Mamon, Jennifer Y. Wo, Lawrence S. Blaszkowsky, Carlos Fernández‐del Castillo, Richard S. Swanson, Brian M. Wolpin, Eunice L. Kwak, Jill N. Allen, Andrew X. Zhu, Jeffrey W. Clark, Raymond Wadlow, David P. Ryan, Theodore S. Hong	0
16	Long‐term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer 2011 ·Cancer ·Nils D. Arvold, David P. Ryan, Andrzej Niemierko, Lawrence S. Blaszkowsky, Eunice L. Kwak, Jennifer Y. Wo, Jill N. Allen, Jeffrey W. Clark, Raymond Wadlow, Andrew X. Zhu, Carlos Fernández‐del Castillo, Theodore S. Hong	57
17	Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab 2011 ·The Oncologist ·Raymond Wadlow, Aram F. Hezel, Thomas A. Abrams, Lawrence S. Blaszkowsky, Charles S. Fuchs, Matthew H. Kulke, Eunice L. Kwak, Jeffrey A. Meyerhardt, David P. Ryan, Jackie Szymonifka, Brian M. Wolpin, Andrew X. Zhu, Jeffrey W. Clark	67
18	Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells 2009 ·Cell ·Claudia Scholl, Stefan Fröhling, Ian F. Dunn, Anna C. Schinzel, David A. Barbie, So Young Kim, Serena J. Silver, Pablo Tamayo, Raymond Wadlow, Sridhar Ramaswamy, Konstanze Döhner, Lars Bullinger, Péter Sandy, Jesse S. Boehm, David E. Root, Tyler Jacks, William C. Hahn, D. Gary Gilliland	416
19	Systems-Level Modeling of Cancer-Fibroblast Interaction 2009 ·PLoS ONE ·Raymond Wadlow, Ben S. Wittner, (unknown), (unknown), Rabi Upadhyay, Stephen P. Finn, Massimo Loda, Umar Mahmood, Sridhar Ramaswamy	22
20	Umbilical cord blood transplantation: Where do we stand? 2002 ·Biology of Blood and Marrow Transplantation ·Raymond Wadlow, David Porter	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact